| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1200/JCO.2007.15.7198 |
| P698 | PubMed publication ID | 18640940 |
| P2093 | author name string | S Gail Eckhardt | |
| Avi Ashkenazi | |||
| Pamela Holland | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 3621-3630 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). | |
| P478 | volume | 26 |
| Q58648371 | Q58648371 |
| Q85196462 | A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors |
| Q34989102 | A homeostatic switch in PACS-2 links membrane traffic to TRAIL-induced apoptosis |
| Q40961671 | A new TRAIL in Alzheimer's disease therapy |
| Q39744489 | A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. |
| Q39070728 | A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells |
| Q46960981 | A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres |
| Q38710179 | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis |
| Q38960411 | AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L. |
| Q41712371 | Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma |
| Q26749384 | Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development |
| Q37952804 | Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy? |
| Q24301064 | Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity |
| Q39790634 | Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer |
| Q52888457 | Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. |
| Q36432437 | Apoptosis induction of human prostate carcinoma DU145 cells by diallyl disulfide via modulation of JNK and PI3K/AKT signaling pathways |
| Q38783727 | Apoptotic Cell Death Induced by ofLBP6A, Lipopolysaccharide Binding Protein Model Peptide, Derived from Paralichthy olivaceus on MKN-28 Cells |
| Q39667395 | B cell receptor triggering sensitizes human B cells to TRAIL-induced apoptosis |
| Q34973290 | Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation |
| Q37628296 | Breast carcinoma progression and tumour vascular markers related to apoptotic mechanisms |
| Q38851998 | CAPE Analogs Induce Growth Arrest and Apoptosis in Breast Cancer Cells. |
| Q38807514 | CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies |
| Q36629546 | Caspase induction and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alteration |
| Q35051505 | Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level |
| Q83974098 | Chemotherapy-resistant metastatic breast cancer |
| Q45872444 | Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer |
| Q36762882 | Clinical targeting of the TNF and TNFR superfamilies |
| Q35919697 | Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics |
| Q42063450 | Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions |
| Q36342896 | Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models |
| Q37761322 | Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? |
| Q39126075 | Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling |
| Q46311702 | Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk |
| Q55312940 | Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations. |
| Q36654392 | Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo. |
| Q42123656 | Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function. |
| Q39138922 | Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection |
| Q38103591 | Death receptors as targets in cancer |
| Q36140704 | Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain |
| Q37073589 | Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects |
| Q36395984 | Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors |
| Q35184454 | Deoxypodophyllotoxin isolated from Juniperus communis induces apoptosis in breast cancer cells |
| Q59134014 | Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells |
| Q53701901 | Developing TRAIL/TRAIL death receptor-based cancer therapies. |
| Q35381023 | Different apoptotic pathways activated by oxaliplatin in primary astrocytes vs. colo-rectal cancer cells |
| Q37319386 | Directing cancer cells to self-destruct with pro-apoptotic receptor agonists |
| Q40822940 | Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. |
| Q34806765 | Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. |
| Q37997559 | Dual targeting strategies with bispecific antibodies |
| Q48897293 | Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study |
| Q21136372 | Dynamic computational model suggests that cellular citizenship is fundamental for selective tumor apoptosis |
| Q33723716 | Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. |
| Q39028542 | Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice |
| Q55396225 | Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. |
| Q35006015 | Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts |
| Q43013506 | Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells |
| Q37540968 | Emerging biological treatments for uterine cervical carcinoma. |
| Q37482834 | Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity |
| Q39941071 | Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies |
| Q39360115 | Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells |
| Q34075052 | Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. |
| Q35590091 | Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. |
| Q35978089 | Ethanolic extract of Descurainia sophia seeds sensitizes A549 human lung cancer cells to TRAIL cytotoxicity by upregulating death receptors |
| Q35653933 | Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours |
| Q39071318 | Experiment research on inhibition of glioma with sTRAIL in vitro |
| Q36338510 | Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines |
| Q39831266 | Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma |
| Q39672002 | Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors |
| Q61799891 | Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization |
| Q90449727 | Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses |
| Q90733230 | Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile |
| Q36214554 | Gli2 silencing enhances TRAIL-induced apoptosis and reduces tumor growth in human hepatoma cells in vivo |
| Q28729017 | Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis |
| Q34285051 | Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q51373757 | Highly sensitive antibody-free μLC-MS/MS quantification of rhTRAIL in serum. |
| Q35754482 | Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation |
| Q38806320 | Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects |
| Q30854013 | Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells |
| Q36777316 | Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand |
| Q59224646 | In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody |
| Q39162763 | Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells. |
| Q36070101 | Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. |
| Q35063836 | Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy |
| Q33803816 | Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells |
| Q35147669 | Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis |
| Q52663605 | Intracellular Desmoglein-2 cleavage sensitizes epithelial cells to apoptosis in response to pro-inflammatory cytokines. |
| Q34609399 | Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. |
| Q39644411 | Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Glioma Therapy |
| Q35827410 | Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer? |
| Q38255704 | Leukocytes as carriers for targeted cancer drug delivery |
| Q35976605 | Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells |
| Q34608366 | Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery |
| Q58805859 | Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death |
| Q34524741 | MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression |
| Q33630657 | Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling |
| Q38938230 | Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas |
| Q36339240 | Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells |
| Q38235124 | Mitochondria-mediated apoptosis in mammals |
| Q37517140 | Mix to validate: a facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo |
| Q39017730 | Modulation of apoptosis-related cell signalling pathways by curcumin as a strategy to inhibit tumor progression |
| Q36482809 | Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. |
| Q39815318 | Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer |
| Q38072888 | Molecular mechanisms of curcumin action: signal transduction |
| Q38275427 | Multifunctional adamantane derivatives as new scaffolds for the multipresentation of bioactive peptides |
| Q39226253 | Multimerization of an apoptogenic TRAIL-mimicking peptide by using adamantane-based dendrons. |
| Q92106879 | Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy |
| Q38931192 | Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction |
| Q38968034 | Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells |
| Q42041489 | NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis. |
| Q50070105 | Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy. |
| Q37473651 | Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery |
| Q47707153 | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. |
| Q39673949 | Naringenin up‐regulates the expression of death receptor 5 and enhances TRAIL‐induced apoptosis in human lung cancer A549 cells |
| Q34022690 | New insights into apoptosis signaling by Apo2L/TRAIL. |
| Q57162853 | Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond |
| Q54455848 | Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated death receptor 5 expression. |
| Q35023172 | Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine |
| Q47712951 | Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer |
| Q37426156 | Phellinus linteus polysaccharide extracts increase the mitochondrial membrane potential and cause apoptotic death of THP-1 monocytes |
| Q46603509 | Phenethyl isothiocyanate enhances TRAIL-induced apoptosis in oral cancer cells and xenografts. |
| Q33695003 | Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells |
| Q37719266 | Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis |
| Q37585453 | Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma |
| Q40994131 | Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction |
| Q39069268 | Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways |
| Q35643014 | Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells |
| Q39792494 | Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation |
| Q41813196 | Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-κB-STAT3-directed gene expression |
| Q35480734 | Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion |
| Q35213333 | Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy |
| Q39721558 | Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines |
| Q39673837 | Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor−related apoptosis-inducing ligand-mediated apoptosis |
| Q35158520 | Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis |
| Q36848141 | Resveratrol: Biological and pharmaceutical properties as anticancer molecule |
| Q38097425 | Role of T cell death in maintaining immune tolerance during persistent viral hepatitis |
| Q33421148 | Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity |
| Q35080496 | Senescence-secreted factors activate Myc and sensitize pretransformed cells to TRAIL-induced apoptosis |
| Q58547260 | Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism |
| Q53700386 | Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin. |
| Q39714230 | Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation |
| Q39215637 | Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. |
| Q35005616 | Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis |
| Q51431947 | Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain-FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study. |
| Q34184469 | Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways |
| Q35230726 | Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis |
| Q39801855 | Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. |
| Q43098453 | Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells |
| Q41778655 | Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels. |
| Q37029804 | Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells |
| Q60469434 | Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients |
| Q37440765 | TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies |
| Q36586540 | TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma |
| Q48217382 | TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors |
| Q38750240 | TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models |
| Q37016549 | TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. |
| Q42249160 | TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma |
| Q33674881 | TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo |
| Q37433463 | TRAIL on trial: preclinical advances in cancer therapy |
| Q60960591 | TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase |
| Q35138611 | TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans. |
| Q33916314 | TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT |
| Q38352891 | TRAIL-based therapy in pediatric bone tumors: how to overcome resistance |
| Q37519654 | TRAIL-coated leukocytes that kill cancer cells in the circulation |
| Q42065026 | TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer |
| Q37889112 | TRAIL-mediated signaling in prostate, bladder and renal cancer |
| Q34809370 | Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis |
| Q35609438 | Targeted ovarian cancer treatment: the TRAILs of resistance. |
| Q38120535 | Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy |
| Q35613406 | The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells |
| Q36511919 | The TRAIL to targeted therapy of breast cancer |
| Q33815463 | The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines |
| Q39856408 | The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment |
| Q38981224 | The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells |
| Q33442825 | The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells |
| Q35884130 | The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition |
| Q41978994 | The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer |
| Q36992184 | The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells |
| Q41714576 | Thioether analogues of disulfide-bridged cyclic peptides targeting death receptor 5: conformational analysis, dimerisation and consequences for receptor activation |
| Q41051062 | Trail (TNF-related apoptosis-inducing ligand) induces an inflammatory response in human adipocytes |
| Q37275272 | Trail overexpression inversely correlates with histological differentiation in intestinal-type sinonasal adenocarcinoma. |
| Q28391040 | Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells |
| Q60919975 | Tubulin couples death receptor 5 to regulate apoptosis |
| Q37621564 | Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy |
| Q42091109 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. |
| Q36218165 | Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model |
| Q33636849 | Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. |
| Q37341171 | Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. |
| Q41440890 | miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling. |
| Q39520220 | shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis |
Search more.